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A cognate aptamer duo for visceral adipose tissue-derived serpin (vaspin) which distinctively bind to two
different sites on vaspin with high afﬁnity and speciﬁcity were successfully developed by using graphene
oxide-based systematic evolution of ligands by exponential enrichment (GO-SELEX), which offers im-
mobilization-free screening of aptamers. The speciﬁc and simultaneous bindings of this aptamer duo (V1
and V49 aptamers) to the different sites of vaspin were conﬁrmed by circular dichroism (CD) analysis and
both sandwich-type surface plasmon resonance (SPR) and quantum dot labelled ﬂuorescence imaging
analysis (V1 aptamer serves as primary capturing aptamer and V49 aptamer as secondary signalling
aptamer or vice versa). With this vaspin cognate aptamer duo on SPR platform, the detection of the target
vaspin were improved to the limit of detection down to 3.5 ng/ml in buffer and 4.7 ng/ml in human
serum samples. This cognate aptamer duo based biosensor could be utilized in the early diagnosis of
type-2 diabetes.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Since the ﬁrst oligonucleotide inhibitors that can bind to two
different distinct epitopes of human thrombin was reported
(Tasset et al., 1997), a broad adoption of thrombin dual aptamers
has evolved in the successful development of novel analytical
techniques, and molecular diagnostic applications (Lee et al., 2013;
Liu et al., 2013a; Vinkenborg et al., 2011). Dual aptamers or even
aptamer cocktails (Kim et al., 2014) offer an advanced biosensor
and molecular system modiﬁcations, by mostly implementing one
aptamer as capturing probe and another aptamer as signalling
probe. Moreover, the use of dual aptamers was proved to provide a
higher binding afﬁnity and speciﬁcity to their target protein than
the use of any of the individual aptamers alone (Jo et al., 2014;
Rinker et al., 2008). By taking advantage of the superiority of ap-
tamers towards antibodies, such as aptamers can be synthesized
chemically and easily modiﬁed for wide applications, its thermo-
stability, and low production cost, the production of dual aptamers
are pressingly needed. For example, the use of dual aptamers that
can bind to different sites of a target protein could be im-
plemented to a signiﬁcant sandwich platform with an improved
performance over commonly used antibody pairs sandwich for-
mat, the enzyme-linked immunosorbent assay (ELISA) (Zhao et al.,
2011). The sandwich format biosensor is widely adopted for theB.V. This is an open access article udetection of targets due to its ﬂexible modiﬁcation to generate
signal. Moreover, easy modiﬁcation of aptamer over antibody,
which is not reducing its afﬁnity to target, the dual aptamer de-
velopment is indispensable.
However, the approaches to generate dual aptamers remain as
a big challenge, with only few studies reported, to date, that re-
quire special yet complicated engineering techniques, such as the
use of other ligands (Shi et al., 2007) and SELEX-RNA pool (Gong
et al., 2012) as competitive inhibitors to challenge aptamer selec-
tion to different surfaces of the target proteins. These approaches,
however, need unpromising ﬁrstly produced high afﬁnity apta-
mers pool for further screening of secondary aptamers, which
requires additional selection rounds, time and cost, and low ex-
posure of target surfaces due to immobilization of protein targets
on separation carrier such as magnetic beads. Previously, an efﬁ-
cient immobilization-free screening of aptamers assisted by gra-
phene oxide (GO-SELEX) method was successfully developed in
our laboratory by taking advantage on the interaction between
oligonucleotides and graphene (Park et al., 2012). Interestingly,
this immobilization-free of target increases target's surface ex-
posure and chances for binding between ssDNAs and the target
protein, which therefore increases the possibility of more than one
aptamer to bind to a target naturally, at a time.
Vaspin is an adipokine which is known as a marker for insulin
resistance involved in obesity and type-2 diabetes (Kloting et al.,
2007; Van Harmelen et al., 1998). This protein marker was ﬁrst
identiﬁed from visceral adipose tissue in a rat model of obesity and
type 2 diabetes (Hida et al., 2005), found to play roles in obesitynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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However, the mechanisms behind the mode of action of vaspin
and its molecular targets are still unknown (Bluher, 2012).
Therefore, the production of aptamer targeting vaspin is required
for further investigations on the mechanisms and also for the
development of novel strategies in alleviating obesity and diabetes
diseases in human. Hence, in this study, we successfully generate a
cognate aptamer duo for visceral adipose tissue-derived serpin
(vaspin) and further characterize the binding of this aptamer duo
to two distinct vaspin sites with high afﬁnity and speciﬁcity.2. Material and methods
2.1. Selection of vaspin speciﬁc ssDNA aptamers
The GO-SELEX process was performed by initially heating
200 pmoles of random library consisting a randomized region of
30 (N30) nucleotides ﬂanked by two constant regions allowing
primer annealing and PCR ampliﬁcation (primer sequences: FP 5′-
CGTACGGAATTCGCTAGC-3′ and RP 5′-GGATCCGAGCTCCACGTG-
3′), at 95 °C for 15 min and then cooling for 5 min on ice for the
best conformational structure of oligonucleotides. First round of
SELEX started with the denatured ssDNA library, which then was
incubated with a counter-target mixture in binding buffer
(100 mM NaCl, 20 mM Tris–HCl, 2 mM MgCl2, 5 mM KCl, 1 mM
CaCl2, pH 7.6) that included four other adipokine proteins which
are adiponectin, visfatin, retinol-binding protein 4 (RBP4) and re-
sistin, and human serum albumin (HSA). The counter selection was
performed at every selection round to remove ssDNA that bound
to the counter targets, which are very similar to the target in terms
of molecular structure and properties. After 30 min incubation on
slow rotator, 4 mg of GO was added and incubated for 2 h (ﬁnal
volume 1 mL) in order to separate the oligonucleotides that did
not bind to the counter targets. The solution was centrifuged atFig. 1. Selection of ssDNA aptamers for vaspin by GO-SELEX. (a) The schematic diagram
speciﬁc aptamers during GO-SELEX. (c) The speciﬁcity of the selected aptamers V1, V3, V4
(SPR) analysis. (d) Dose-dependent saturation plots for vaspin binding to aptamers V1,14,680 rpm for 10 min to precipitate the GO and the supernatant
was discarded. Then, the ssDNA was recovered from GO with the
addition of target vaspin (45 kDa). The supernatant had undergone
ethanol precipitation and the DNA concentration was measured by
nanodrop (Nanodrop, ND-1000, spectrophotometer). The obtained
library pool was ampliﬁed by PCR (for PCR ampliﬁcation, FP 5′-
ﬂuorescein-CGTACGGAATTCGCTAGC-3′ and RP 5′-GGATCC-
GAGCTCCACGTG-3′ were used) and ssDNA was again generated by
PAGE separation and puriﬁcation. The ssDNA obtained from each
round were used as initial ssDNA pool for the following round. All
procedures described previously were repeated until the recovery
of ssDNA reached saturation. Next, cloning and sequencing were
performed to obtain the aptamer sequences. All oligonucleotides
sequencing and systhesis services were purchased from Genotech,
Korea, and all chemicals used in this study were purchased from
Sigma Aldrich (U.S.A). All adipokines used in this study were
purchased from Adipogen, Korea.
2.2. Characterization of selected aptamers by SPR
The selected aptamers obtained from GO-SELEX were char-
acterized using SPR-based analysis. First, SPR gold chip was pre-
pared following previously reported studies (Lee et al., 2008; Liu
et al., 2013b). The SPR gold chip (K-MAC, Korea) was washed with
ethanol and distilled water. The clean chip was then immersed in
50 mM DTPA solution (diluted in 100% ethanol) at room tem-
perature overnight. Then, carboxyl functional groups on chip sur-
face were activated with 200 mM of N-ethyl-N′-(dimethylamino-
propyl) carbodiimide (EDC) and 50 mM of N-hydroxysuccinimide
(NHS) for 30 min. After that, chip was incubated with 100 mg/ml
streptavidin for 90 min on ice. The non-reacted functional groups
were blocked by addition of 50 mM ethanolamine solution for
30 min. Then 5′-T10-biotin labelled aptamers were incubated
(0.5 mM) for 60 min at room temperature. Finally the chip was
blocked with 50 mg/ml BSA solution for 30 min and washed withof advanced screening method of vaspin by GO-SELEX. (b) Enrichment of vaspin-
, V7, V14, V16, V21, V23, V30, V42 and V49 for vaspin by surface plasmon resonance
V4, V14 and V49 obtained by surface plasmon resonance SPR analysis.
Fig. 2. Characterization of cognate aptamer duo for vaspin detection (a) Screening of aptamer duo for vaspin detection using sandwich-type SPR based assay. 0.5 mM of
biotin-labelled primary aptamer was immobilized on SPR gold chip. 0.5 mM of vaspin was immobilized on primary aptamer followed by washing step to remove unbound
vaspin (baseline after washing step was measured [1]) (Fig. S1). Then, 1 mM of bare secondary aptamer was added and unbound secondary aptamer was washed out [2].
Response unit of baseline [2]–[1] was measured. (b) Circular dichroism (CD) analysis of vaspin aptamer duo with and without vaspin, and with and without vaspin aptamer
duo combination.
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was performed using Eco Chemie Autolab SPR instrument (Neth-
erlands) by generating baseline (using same binding buffer used in
SELEX process) for 5 min and binding by injection of 50 ml of each
counter targets and main target for 30 min with a 5 min dis-
sociation time at room temperature. After speciﬁcity analysis for
all 11 aptamer candidates, 4 selected aptamers with high speciﬁ-
city to vaspin were further analyzed with dose dependently and
dissociation constant (Kd value) was determined with nonlinear
regression analysis.
2.3. Preparation of AuNPs-reporter aptamer conjugates for signal
enhancement
10 ml of 5′-thiolated reporter aptamer with C6 spacer (50 mM)
was stabilized with 10 mM of Tris-(2-carboxyethyl) phosphine
hydrochloride (TCEP) (2 ml), and incubated 1 h at room tempera-
ture. 1 mL of prepared AuNPs was transferred to NaOH-treated
tube and 10 ml of thiolated reporter aptamer which had been
stabilized with TCEP was added. AuNPs–aptamer mixture was
incubated for at least 16 h at room temperature. Buffer containing
500 mM Tris acetate pH 8.2 and 1 M NaCl were added dropwise
with gentle hand shaking. The samples were incubated for at least
24 h. Free-thiolated aptamer was removed by centrifugation at
16,000 rcf for 25 min. Precipitates were washed with 5 mM Tris–
HCl pH 7.4 for three times. 6-Mercapto-1-hexanol (MCH) was used
for efﬁcient blocking of unoccupied region on AuNPs surface. MCH
with ﬁnal concentration 10 mM was added to aptamer-modiﬁedAuNPs conjugates and incubated at RT for 30 min and stored at 8 h
in 4 °C. After blocking, the conjugates were washed with 5 mM
Tris–HCl (2 times) and stored in 4 °C. Several concentrations of
prepared AuNPs were tested on SPR gold chip for non-speciﬁc
adsorption test and full recovery of AuNPs were obtained at con-
centration of 1 nM. The concentration of aptamer modiﬁed-AuNPs
conjugates used in this study was ﬁxed at 0.5 nM with 1:1000
ratio to aptamer concentration immobilized on gold chip (0.5 mM),
following previously reported study (Park et al., 2014).
2.4. Immobilization of cognate aptamer duo on magnetic bead and
quantum dot for confocal microscopy analysis
Immobilization of the biotinylated probes on the surface of the
streptavidin coated QDs and MBs was achieved using the avidin–
biotin interaction, following previously reported protocol (Kim et al.,
2006). Qdotss 525 streptavidin conjugate (Molecular Probes, Life
Technologies Corp., Carlsbad, CA, USA) and beads (Dynabeads MyOne
Streptavidin C1, diameter 1 mm), were purchased from Dynal Biotech
Inc. (Lake Succes, NY, USA). First 10 ml of QD 525 streptavidin con-
jugates (0.1 mM) were incubated with 10 mL 5′-T10-biotinylated V49
aptamer (0.5 mM) and 5′-T10-biotin-BVDV34 aptamer (5′-CGTACG-
GAATTCGCTAGCCGCTCGGGGCGCTGCACGTAGGGTGGGGTGGGATCCG-
3′) in 200 ml of borate buffer (50 mM, pH 8.3) for 1 h at room tem-
perature. The BVDV34 aptamer was chosen by randomly picked as a
random aptamer sequence in a negative control. Themolar ratio of the
aptamer/QDs was 5:1. The magnetic beads (MB) coated with strep-
tavidin were functionalized with 5′-biotinylated ssDNA (V1 aptamer)
Fig. 3. Vaspin cognate aptamer duo binding assay with QD-labelled V49 reporter
aptamer for confocal laser scanning microscopy (CLSM) analysis. (i) In the absence
of target vaspin, and (ii) V49-Qd reporter aptamer, no ﬂuorescent could be seen on
the streptavidin coated magnetic bead. The scale bar is a 1 mm.
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50 μl of the streptavidin modiﬁed magnetic beads (10 mg/mL, approx.
7–12109 beads) were washed two times with 100 μL of 2
Binding & Washing (B&W) buffer (10 mM Tris–HCl, pH 7.5, 1 mM
EDTA, 2.0 M NaCl) to remove any preservatives and then resuspended
in 100 μl of 2 B&W buffer. Next, 100 μl of the MB-probes (10 μM),
in distilled water, were mixed with the washed MBs suspension and
incubated for 10 min at room temperature with gentle agitation. The
magnetic beads, now coated with MB-probes, were separated from
the weakly bound MB-probes and washed three times with 1 B&W
buffer using a magnet.
2.5. Circular dichroism spectroscopy analysis
The CD spectrums of the 1 mM DNA aptamer and 2 mM of vaspin
were analyzed from 320 to 210 nm wavelengths using circular
dichroism spectrometer (Applied Photophysics, UK). The data ob-
tained were the average of four scans at a scanning rate of 100 nm/
min. The scan of the binding buffer recorded at room temperature
was subtracted from the average scans.
2.6. Detection of vaspin in human serum samples using cognate
aptamer duo-based SPR analysis
The dose dependent binding assay was performed using
0–2.5 nM of ﬁnal concentration of vaspin spiked in 10-fold dilutedhuman serum samples. Human serum (from human male AB
plasma, Sigma Aldrich, USA) was diluted to reduce the ion strength
and interference from abundant complex in the serum (Zhang
et al., 2009). The binding assays were performed using 0.5 mM V1
aptamer conjugated on SPR gold chip and 0.5 nM AuNPs–V49
aptamer conjugates. All of binding assays were performed in tri-
plicate and the detection limit was calculated by using blank
sample (buffer)þ3 standard deviations (SDs).3. Results and discussion
3.1. Selection of vaspin speciﬁc ssDNA aptamers
The vaspin-binding aptamers selection was performed by using
the GO-SELEX method as illustrated in Fig. 1a. The ssDNA library
was ﬁrstly incubated with a counter target mixture consisting four
other adipokine proteins which are adiponectin, visfatin, retinol-
binding protein 4 (RBP4) and resistin, and human serum albumin
(HSA). These counter targets were chosen based on their similar
structure to vaspin and belongs to the same adipokine group. The
counter selection step was performed at every selection round to
increase the selectivity of ssDNA to target vaspin by the efﬁcient
removal of ssDNA non-speciﬁc binding. Then, the ssDNAs which
bound to the counter targets were removed by centrifugation (in
supernatant), leaving the unbound ssDNAs that adsorbed onto GO
through phi–phi stacking interactions. After vaspin target was
added, the ssDNAs detached from GO and bound to vaspin by
target-induced afﬁnity-based detachment. This SELEX procedure
was brieﬂy described in the method section. The fraction of
ssDNAs eluted from each selection round was increased from
round 1 to round 5 with recovery yield up to 90% of the inlet
ssDNA pool and reached saturation state as can be seen in Fig. 1b.
As a result, 42 sequences of ssDNA aptamer candidates were ob-
tained after cloning and sequencing of 5th round ssDNA pool.
Furthermore, we selected 11 sequences of aptamer candidates
ranked by Gibb’s free energy for further analysis (Table S1). Fig. 1c
shows the speciﬁcity of 11 selected aptamer candidates, V1, V3, V4,
V7, V14, V16, V21, V23, V30, V42 and V49 for vaspin based on SPR
analysis. From the speciﬁcity analysis of the selected 11 aptamer
candidates with ﬁve counter targets, four aptamers (V1, V4, V14
and V49) were found to have highly speciﬁc binding only to vaspin
with no or very low binding to other ﬁve counter targets (nampt,
adiponectin, resistin, RBP4 and human serum albumin (HSA)).
Thus, the binding afﬁnities of these four aptamers were evaluated
and their dissociation constant (Kd) values were measured to be
0.17, 0.31, 0.28 and 0.24 mM, for V1, V4, V14 and V49, respectively
(Fig. 1d), analyzed by SPR.
3.2. Characterization of cognate aptamer duo for vaspin detection
The binding of four single aptamers with vaspin was found to
be concentration dependent in a range from 25 nM to 2 mM of
target. We further investigated the possibilities of having sec-
ondary interactions amongst four selected aptamers, to develop
novel cognate aptamer duo for vaspin, which can bind to two
different epitopes on vaspin. All 12 possible combinations of pri-
mary and secondary aptamers for 4 aptamers were tested and we
found that the combination of V1 and V49 aptamers were shown
to have binding interactions for both primary and secondary po-
sitions, indicating that these aptamer duo bind distinctively to
different site on vaspin surfaces and the combination is in har-
mony (Fig. 2a). In addition, V1 aptamer was preferred to be the
primary aptamer and V49 as the secondary aptamer, because this
cognate aptamer duo combination produced higher SPR response
unit (RU) signal compared to the reverse combination. Thus, V1
Fig. 4. Vaspin cognate aptamer duo enhanced vaspin detection via gold-nanoparticle (AuNPs) conjugation using SPR-based assay. (a) Schematic diagram of sandwich-type
application of the developed vaspin aptamer duo. After the development of vaspin cognate aptamer duo, primary aptamer (V1 aptamer) was used as capturing probe and the
secondary aptamer was used as reporting probe in the signal enhanced SPR-based biosensor platform. (b) Dose-dependent binding assays by using single and cognate
aptamer duo for vaspin detection measured by SPR-based analysis. The inset ﬁgures showed enlarged spectrum analysis of lower vaspin concentration for single and cognate
aptamer duo from 0 to 100 nM and 0 to 2.5 nM, respectively. The error bars represent average standard errors for three replicates. Each binding reaction were carried out by
using 0.5 mM V1 aptamer conjugated on SPR gold chip and 0.5 nM AuNPs–V49 aptamer conjugates.
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porting aptamer for vaspin detection in further investigations.
The binding of this cognate aptamer duo combination to vaspin
was also conﬁrmed by circular dichroism (CD) analysis. As shown
in Fig. 2b, upon addition of vaspin, V1 and V49 aptamers changed
to different peak patterns compared to their own CD spectrum
without vaspin. Moreover, in the presence of vaspin, the intense
negative peak at 275 nm from the individual CD spectrum of V49
aptamer and a negative peak at 220 nm from the V1 aptamer CD
spectrum, proving that both V1 and V49 aptamers have different
structural conformations upon binding to vaspin. Hence, theseevidences strongly supported that this aptamer duo has a sig-
niﬁcantly different secondary structure (also was shown by M-fold
software prediction in Fig. S2), showing that these two aptamers
naturally bind to different epitopes of vaspin, in consistent with
previously reported study (Luo et al., 2013) for antitoxyplasma IgG
dual aptamers case.
3.3. Vaspin cognate aptamer duo binding assay with QD-labelled
V49 reporter aptamer
By having this cognate aptamer duo for vaspin detection, the
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in Fig. 3, by using the same sandwich format as SPR-based assay,
we further visualized this aptamer duo binding on vaspin by using
quantum dot labelled-V49 reporter aptamer. The biotin labelled V1
aptamer was used as primary aptamer conjugated on streptavidin
coated magnetic bead and biotin labelled V49 secondary aptamer
was then conjugated on streptavidin coated quantum dot. From
the confocal laser scanning microscopy (CLSM) analysis, high sig-
nal of ﬂuorescent could be seen only with the presence of vaspin
(0.5 mM) together with the aptamer duo combination, while no
ﬂuorescence could be observed in control 1 (with the absence of
vaspin) and control 2 (using other aptamer replacing V49 reporter
aptamer).3.4. Enhanced vaspin detection using vaspin cognate aptamer duo
via gold-nanoparticle (AuNPs) conjugation
The biggest advantage of having cognate aptamer duo is an easy
and broad modiﬁcation of capturing and reporting aptamers in
order to enhance the detection of target in sensing platform. Since
the sandwich-type SPR-based assay using bare V49 reporting ap-
tamer showed only a small increment in the SPR signal, we there-
fore performed signal enhancement approach by conjugating
AuNPs to the V49 reporting aptamer (Fig. 4a). As can be seen in
Fig. 4b, the aptamer conjugated with AuNPs sandwich system
showed highly enhanced response unit on SPR sensor platform
compared to the use of single aptamer. From the plotted SPR re-
sponse unit in the inset Fig. 4b, detection limit was calculated by
using blank sample (buffer)þ3 standard deviations (SDs) for single
and cognate aptamer duo systems which were found to be
399.7 ng/ml (8.9 nM) and 3.5 ng/ml (78 pM), respectively. Thus, the
sensitivity was improved for about 114-fold increased for vaspin
detection. In addition, the detection limit of vaspin in this study was
within vaspin physiological range of interest (0.1–7 ng/ml).Table 1
The comparison of vaspin detection limit from each aptasensing platform for the
detection of vaspin.
Platform Limit of detection (ng/
ml)
Note
Single aptamer 399.7 In this study
Cognate aptamer duo sandwich
with AuNPs
3.5 (in buffer) 4.7 (in
human serum)
In this study
Single aptamer 1150 Kim (2010)
Vaspin binding aptamer-antibody
sandwich (ELAAS)
39 Lee et al.
(2012)
Fig. 6. Competitive binding assay of cognate aptamer duo to two different sites of vaspi
gold chip and 0.25 mM of vaspin.3.5. Detection of vaspin spiked in human serum samples using cog-
nate aptamer duo-based SPR analysis
We analyzed the detection of vaspin spiked in human serum
samples to demonstrate the ability of the cognate aptamer duo-
based SPR system to detect vaspin in the biologically complex
matrices. The same range of vaspin concentrations was used for
the detection of vaspin spiked in human serum samples as in the
binding buffer condition. From Fig. 5, the results show that the
detection limit of vaspin spiked in human serum was found to be
0.1 nM (4.7 ng/ml) of vaspin, which is slightly higher than in the
buffer condition but still within the physiological range of interest.
This result supports that the vaspin cognate aptamer duoFig. 5. Detection of vaspin spiked in human serum samples by using cognate ap-
tamer duo-based SPR analysis. (a) SPR spectra and (b) response unit plot of dose
dependent vaspin concentration spiked in human serum samples ranging from 0 to
2.5 nM. The binding assays were performed using 0.5 mM V1 aptamer conjugated
on SPR gold chip and 0.5 nM AuNPs–V49 aptamer conjugates. The error bars re-
present average standard errors for three replicates.
n. The binding assays were performed using 0.5 mM V1 aptamer conjugated on SPR
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trices in human serum. Moreover, as shown in table 1, the use of
vaspin cognate aptamer duo in this study was found to be com-
petitive and possess the best sensitivity for vaspin detection with
the use of aptamer. More importantly, this cognate aptamer duo is
more ﬂexible to be used with wide modiﬁcation techniques on
sandwich manners, and cost effective compared to the use of en-
zymes or antibodies.
3.6. Competitive binding assay of cognate aptamer duo on two dif-
ferent sites of vaspin
We performed competitive binding assays which targeted V49
aptamer binding site on vaspin. V49 bare aptamer was used to com-
pete with V49–AuNPs aptamer conjugates binding on vaspin which
caused reduction of SPR signal due to the decreasing amount of V49–
AuNPs aptamer conjugates bound to vaspin. From Fig. 6, the reduction
in the signals was observed when higher ratio of V49–AuNPs aptamer
conjugates to V49 bare aptamer was added, but no reduction was
observed in both cases that V49–AuNPs aptamer conjugates only or
V49–AuNPs aptamer conjugates and V1 aptamer bare were added.4. Conclusion
In summary, an advanced immobilization-free SELEX method was
successfully adopted for screening of a novel cognate aptamer duo for
vaspin detection. GO-SELEX was used due to the immobilization-free
screening of aptamers which increases the surface exposure of vaspin
target and chances for ssDNA binding, which therefore, increases the
possibility of having more than one cognate aptamers binding to the
different sites of a single target distinctively at one time. V1, V4, V14
and V49 aptamers were found to have high speciﬁcity to vaspin, while
discriminating ﬁve other counter targets (adiponectin, visfatin, retinol-
binding protein 4, resistin and human serum albumin), based on the
surface plasmon resonance (SPR) analysis. The dissociation constant
(Kd) value for the four aptamers were found to be 0.17, 0.31, 0.28 and
0.24 mM for V1, V4, V14 and V49 aptamers, respectively, analyzed by
SPR-based assay. For the ﬁrst time, a cognate aptamer duo was de-
veloped using immobilization free-GO SELEX for a protein target. V1
and V49 aptamers were found to display vaspin cognate aptamer duo,
conﬁrmed by CD and both sandwich-type SPR and quantum dot la-
belled ﬂuorescence imaging analysis. Vaspin detection was also im-
proved using gold-nanoparticles (AuNPs) conjugation on the V49 re-
porter aptamer, with enhanced limit of detection down to 3.5 ng/ml
(114-fold increased) compared to the detection by using single apta-
mer. The detection limit of vaspin spiked in human serum was found
to be 0.1 nM (4.7 ng/ml) of vaspin, which is slightly higher than in the
buffer condition but still within the physiological range of interest.
This novel cognate aptamer duo can be applied to various modiﬁca-
tions in improving aptasensor, helps in the generation of new nano-
materials, as well as development of novel strategies in alleviating
obesity and diabetes diseases in human.Acknowledgments
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